Syncona to Acquire Freeline Therapeutics

Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...

November 23, 2023 | Thursday | News
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...

November 14, 2023 | Tuesday | News
Charles River and Aitia Partner to Advance Logica in Neurodegenerative and Oncology Discoveries

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...

November 14, 2023 | Tuesday | News
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays

Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces a collaboration with Uli...

November 13, 2023 | Monday | News
Senti Bio Collaborates with Celest Therapeutics to Advance SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...

November 07, 2023 | Tuesday | News
Pfizer Advances GLP-1 Receptor Agonist PF-06954522 to Phase 1 Trial with Sosei Heptares Collaboration

Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has been notified by Pfizer that it has entered a new oral s...

November 06, 2023 | Monday | News
Singapore's Engine Biosciences Secures $27M in Series A Extension for Precision Oncology Development and Biomarker Research

Funds to support translation of R&D programs derived from proprietary NetMAPPR machine learning network biology platform and CombiGEM combinatorial gen...

November 02, 2023 | Thursday | News
Aldeyra Therapeutics and AbbVie Sign Exclusive Option Agreement for Reproxalap License

Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...

November 02, 2023 | Thursday | News
Coherus and Junshi Biosciences Secure FDA Approval for LOQTORZI™ in All NPC Treatment Lines

Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum containing ...

October 30, 2023 | Monday | News
Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus

Under the planned partnership, Ginkgo and the Serbian Ministry of Science, Technological Development and Innovation will work to establish a Startup Accele...

October 23, 2023 | Monday | News
ERS Genomics completes licensing agreement with Syngene International

ERS Genomics Limited ('ERS') completes licensing agreement with Syngene International, India's leading Contract Research, Development and Manufacturing Org...

October 19, 2023 | Thursday | News
GE Healthcare Inks $44M Deal with BARDA for AI-Enhanced Ultrasound Tech to Boost Trauma Care and Disaster Preparedness

GE HealthCare (Nasdaq: GEHC) today announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA)&mdash...

October 13, 2023 | Friday | News
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture,...

October 12, 2023 | Thursday | News
SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fi...

October 12, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in